Full-Time

Rotational Analyst

Posted on 8/4/2026

Roivant Sciences

Roivant Sciences

201-500 employees

Biopharmaceutical company developing RNA therapeutics

Compensation Overview

$100k/yr

+ Discretionary bonuses + Equity

No H1B Sponsorship

New York, NY, USA

Remote

Relocation to New York, NY is required.

Category
Business & Strategy (1)
Required Skills
Data Science
Biochemistry
Data Analysis

Get referred to Roivant Sciences

See people who can refer or advise you

Requirements
  • Enrollment in a four-year undergraduate university in the United States with an expected graduation date between December 2026 and June 2027.
  • Currently pursuing an undergraduate degree in the life sciences, business, economics, or a related quantitative field, such as Biology, Chemistry, Biochemistry, Economics, Finance, Data Science, or Public Health.
  • Demonstrated interest or experience in healthcare, biotechnology, or the life sciences.
  • A track record of academic excellence, including a GPA of 3.5 or higher.
  • Willingness to relocate to New York, NY.
  • Authorization to work in the United States; the role is not eligible for visa sponsorship, including STEM OPT.
  • Ability to analyze data and translate complex concepts into clear, concise recommendations.
  • Ability to seek information independently, solve conceptual problems, coordinate across teams, and deliver results with minimal direction.
  • Strong multitasking, organizational, and project-planning skills, with the ability to meet aggressive deadlines.
  • Ability to adapt quickly to a rapidly changing environment and solve problems creatively.
Responsibilities
  • Complete four six-month rotations across different teams and functions, including Roivant subsidiaries.
  • Own projects from the beginning of the program and deliver meaningful results.
  • Evaluate in-licensing opportunities to expand Roivant’s portfolio of medicines.
  • Perform literature reviews to identify indication-expansion opportunities in support of subsidiaries.
  • Develop strategies to accelerate clinical-trial recruitment.
  • Create an investor deck in partnership with key executives for a Phase 3 clinical-trial readout.
Desired Qualifications
  • Passion for Roivant’s mission to improve health by rapidly delivering innovative medicines to patients.
  • Curiosity about the intersection between science and technology.
  • Strong verbal and written communication skills.
  • Strong analytical ability and intellectual curiosity.
  • Self-directed approach to solving problems and delivering results.
  • Ability to thrive in ambiguity.
  • Attention to detail and conscientiousness.
  • Creative problem-solving ability and a persistent bias for action.

Roivant Sciences develops and delivers medicines, with a focus on genetic disorders and RNA therapeutics, using in-house R&D plus strategic partnerships. Its subsidiary Genevant uses proprietary delivery platforms to create RNA-based treatments, including mRNA, RNA interference, and gene editing. Revenue comes from developing drug candidates, licensing deals, partnerships, and selling approved drugs, leveraging collaborations to accelerate the pipeline. The goal is to bring effective medicines to patients faster and more efficiently by combining technology platforms with strategic alliances.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2014

Get referred to Roivant Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Brepocitinib has FDA Priority Review for dermatomyositis, with Q3 2026 PDUFA.
  • IMVT-1402 spans multiple autoimmune indications, creating several shots on goal.
  • The company expects over three launches and four NDA or BLA filings soon.

What critics are saying

  • Roivant has no commercial-stage product since Dermavant's sale in October 2024.
  • Brepocitinib approval is still a binary Q3 2026 regulatory event.
  • Batoclimab missed its thyroid eye disease primary endpoint, pressuring the FcRn franchise.

What makes Roivant Sciences unique

  • Roivant builds focused subsidiaries, or Vants, around each asset.
  • Its pipeline centers on late-stage autoimmune and cardiopulmonary programs.
  • It combines drug development with technology-focused Vants to cut development costs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Stock Titan
Dec 11th, 2025
Immunovant prices $550M stock offering to fund IMVT-1402 Graves' disease launch

Immunovant has priced an underwritten common stock offering of 26.2 million shares at $21.00 per share, raising approximately $550 million in gross proceeds. The company expects existing cash plus the proceeds to fund operating expenses and capital expenditures through a potential commercial launch of IMVT-1402 for Graves' disease. Roivant Sciences, Immunovant's controlling stockholder, has agreed to purchase shares in the offering. Leerink Partners is acting as sole underwriter. The offering is expected to close on or about 12 December 2025, subject to customary closing conditions. The shares are being offered pursuant to an automatic registration statement on Form S-3 previously filed with the Securities and Exchange Commission.

PsiThera
Dec 10th, 2025
PsiThera Unveiled with Newly Appointed CEO and $47.5 Million Series A to Advance Oral Medicines for Validated I&I Targets - PsiThera

Watertown, MA, December 10, 2025 — PsiThera, a biotech company harnessing biologically relevant protein states and computational intelligence to create oral drugs for diseases long-constrained by injectable-only approaches, announced today that it has closed a $47.5 million Series A financing and appointed Eric Shaff as Chief Executive Officer. The equity round was led by Samsara Biocapital…

GlobeNewswire
Sep 11th, 2025
Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List

Earning a spot means that Roivant is one of the best companies to work for in the country.

Investing.com
Feb 24th, 2025
Roivant Sciences president Eric Venker sells $1.07 million in shares

Jennifer Humes has been appointed to succeed Kumar as the new Principal Accounting Officer for Roivant Sciences Ltd. and Chief Accounting Officer for Roivant Sciences, Inc.

FinSMEs
Feb 3rd, 2025
Zest Health Raises $13M in Funding

Zest Health, a NYC-based virtual care company focused on treating patients with inflammatory skin diseases, raised $13M in Seed funding